Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 1994;14:824-830

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Heerde, W. L.
Right arrow Articles by de Groot, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Heerde, W. L.
Right arrow Articles by de Groot, P. G.

Arteriosclerosis and Thrombosis, Vol 14, 824-830, Copyright © 1994 by American Heart Association

ARTICLES

Annexin V inhibits the procoagulant activity of matrices of TNF- stimulated endothelium under blood flow conditions

WL van Heerde, KS Sakariassen, HC Hemker, JJ Sixma, CP Reutelingsperger and PG de Groot
Department of Haematology, University Hospital Utrecht, The Netherlands.

A human ex vivo thrombosis model was used to investigate whether recombinant annexin V (rANV) can prevent thrombus formation under venous and arterial blood flow conditions. In this model, blood from an antecubital vein of healthy donors was allowed to flow directly over the extracellular matrix of tumor necrosis factor-stimulated endothelial cells (TNF-ECMs). TNF-ECMs were preincubated with rANV (2.9 mumol/L) for 30 minutes. With this rANV concentration all binding sites present on TNF-ECMs (1.6 +/- 0.5 x 10(12)/cm2) are occupied, and a maximal inhibition was observed in a tissue factor-dependent clotting assay. Fibrin deposition and platelet and leukocyte adhesion were measured on the rANV-treated and nontreated TNF-ECMs. Nontreated TNF- ECMs were used as controls. rANV inhibited fibrin deposition by 81% at a wall shear rate of 100 s-1. A nonsignificant inhibition was also observed at 650 s-1. Platelet-matrix adhesion, which is more prominent at higher shear rates, was significantly decreased by 60% at 100 s-1 but not at 650 s-1. The average leukocyte adherence was nonsignificantly lowered at 100 s-1. Virtually no leukocytes adhered at 650 s-1. The results demonstrated that rANV can inhibit blood coagulation under venous blood flow conditions and may serve as an antithrombotic drug.


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
N. Gaspersic, A. Ambrozic, B. Bozic, J. Majhenc, S. Svetina, and B. Rozman
Annexin A5 binding to giant phospholipid vesicles is differentially affected by anti-{beta}2-glycoprotein I and anti-annexin A5 antibodies
Rheumatology, January 1, 2007; 46(1): 81 - 86.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
E. Camors, V. Monceau, and D. Charlemagne
Annexins and Ca2+ handling in the heart
Cardiovasc Res, March 1, 2005; 65(4): 793 - 802.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. C. H. Lutters, R. H. W. M. Derksen, W. L. Tekelenburg, P. J. Lenting, J. Arnout, and P. G. de Groot
Dimers of {beta}2-Glycoprotein I Increase Platelet Deposition to Collagen via Interaction with Phospholipids and the Apolipoprotein E Receptor 2'
J. Biol. Chem., September 5, 2003; 278(36): 33831 - 33838.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Gonzalez-Conejero, J. Corral, V. Roldan, C. Martinez, F. Marin, J. Rivera, J. A. Iniesta, M. L. Lozano, P. Marco, and V. Vicente
A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients
Blood, August 28, 2002; 100(6): 2081 - 2086.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Thiagarajan and C. R. Benedict
Inhibition of Arterial Thrombosis by Recombinant Annexin V in a Rabbit Carotid Artery Injury Model
Circulation, October 7, 1997; 96(7): 2339 - 2347.
[Abstract] [Full Text]

Home page
 LupusHome page
C. P.M. Reutelingsperger
The Annexins
Lupus, August 1, 1994; 3(4): 213 - 216.
[PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1994 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.